CONNAUGHT FLU VACCINE WITH LIPOSOME ADJUVANTS
Executive Summary
CONNAUGHT FLU VACCINE WITH LIPOSOME ADJUVANTS will be developed through an agreement between Connaught Labs and the Liposome Company. In an April 14 statement, the companies announced that "the influenza project will seek to demonstrate the usefulness of liposomes as vaccine adjuvants (or amplifiers) for viral fragments." Connaught is assuming worldwide marketing rights for the liposome flu vaccine; the Liposome Company will receive research payments, "hurdle payments" as the product moves through clinicals, and royalties from any eventual sales. The companies view the flu vaccine development effort as a precursor to other liposome vaccine development efforts on products for AIDS, cancer and anti-allergy products. The companies explained that viral fragments "by themselves . . . do not elicit the robust immune response needed for long-term immune protection." Liposomes, however, "can act as powerful amplifiers to boost the antibody response by presenting multiple viral fragments to individual cells."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth